SMALL ANIMAL IMAGING FACILITY (SAIF) The mission of the Small Animal Imaging Facility (SAIF) is to advance cancer research by providing cancer center members with powerful imaging technologies and the expertise necessary to successfully integrate imaging sciences into preclinical cancer research. Dr. John D. Hazle serves as director, and Dr. James A. Bankson serves as co-director. The facility includes faculty experts, specially trained staff, and state-of-the-art imaging instrumentation, most of which is not available anywhere else in the cancer center. The SAIF has 3 separate sites across the campus to ensure convenient access to all cancer center members. SAIF imaging laboratories are located on the North Campus adjacent to and contiguous with the small animal vivarium, inside the South Campus Vivarium, and in South Campus Research Building #3. SAIF faculty and staff are available to support all aspects of imaging in preclinical cancer research, from proposal and experiment design through data acquisition, analysis, interpretation, and presentation. Currently, the SAIF has 21 unique pieces of imaging equipment optimized for small animals and a full complement of ancillary equipment for support of animals before, during, and after experiments. The imaging equipment includes 3 high-field magnetic resonance scanners, a low-field permanent magnet magnetic resonance scanner, a dynamic nuclear polarization system for generating hyperpolarized magnetic resonance agents, a microcomputed tomography system, a positron emission tomography/single-photon emission computed tomography/computed tomography scanner, 2 small- animal radiation research platforms, 2 ultrasound systems (1 capable of photoacoustic imaging), a dedicated photoacoustic imaging system, a cabinet X-Ray system, 6 optical imaging systems, and a prototype magnetic relaxometry system (on loan as part of a research agreement). During this grant period, MD Anderson has funded $5,918,344 in capital equipment, and approximately $1.1M has been obtained through NCI Shared or High-end Instrumentation grants. Annual operational funding is $195,521 (20%) from the CCSG, $719,742 (74%) from program income, and $53,413 (6%) of institutional support. During this 6-year grant period, the SAIF served a total of 250 cancer center members, including investigators from all 16 CCSG programs. A total of 87% of all usage was peer-review funded, and the SAIF is requesting $200,057 (20%) from the CCSG in grant Yr44. Overall use has increased 2.7-fold in Yr42 over the average use in the prior funding cycle. The SAIF supported 181 peer-reviewed publications during this reporting period, with 51 (28%) published in journals with IF >10 and 119 (66%) published in those with IF >5.
The specific aims are:
Aim 1 : To maintain a broad range of state-of-the-art imaging instrumentation and dedicated staff that support the preclinical imaging needs of cancer center members;
Aim 2 : To provide consultation, training and support in the planning, acquisition, and analysis of imaging data;
and Aim 3 : To develop and implement new technologies and methods that improve the accuracy and precision of quantitative imaging biomarkers in preclinical cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-43S1
Application #
9997847
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360
Ellrott, Kyle; Bailey, Matthew H; Saksena, Gordon et al. (2018) Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6:271-281.e7
White, Matthew C; Schroeder, Rebecca D; Zhu, Keyi et al. (2018) HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene 37:4413-4427
Abaza, Yasmin; Hidalgo-Lopez, Juliana E; Verstovsek, Srdan et al. (2018) Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85
McGrail, Daniel J; Federico, Lorenzo; Li, Yongsheng et al. (2018) Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9:1317
Li, Carrie J; Jiang, Changying; Liu, Yang et al. (2018) Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther :
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Raber, Benjamin; Bea, Vivian J; Bedrosian, Isabelle (2018) How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am 26:281-288
Li, Roger; Metcalfe, Michael J; Ferguson 3rd, James E et al. (2018) Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121:244-251

Showing the most recent 10 out of 12418 publications